Sanofi (NASDAQ:SNY) Shares Sold by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 81.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 994 shares of the company’s stock after selling 4,398 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Sanofi were worth $48,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Abel Hall LLC increased its stake in shares of Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after buying an additional 194 shares during the period. Keudell Morrison Wealth Management increased its stake in Sanofi by 1.7% in the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after purchasing an additional 217 shares during the last quarter. Bailard Inc. increased its stake in Sanofi by 1.4% in the fourth quarter. Bailard Inc. now owns 16,359 shares of the company’s stock valued at $789,000 after purchasing an additional 220 shares during the last quarter. Old Port Advisors increased its stake in Sanofi by 0.6% in the fourth quarter. Old Port Advisors now owns 36,704 shares of the company’s stock valued at $1,770,000 after purchasing an additional 232 shares during the last quarter. Finally, ORG Partners LLC boosted its holdings in shares of Sanofi by 17.7% in the fourth quarter. ORG Partners LLC now owns 1,681 shares of the company’s stock valued at $81,000 after acquiring an additional 253 shares during the period. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on SNY shares. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Sanofi has a consensus rating of “Buy” and a consensus price target of $60.00.

Sanofi Price Performance

Sanofi stock opened at $58.92 on Tuesday. Sanofi has a one year low of $45.22 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The business has a fifty day moving average of $53.85 and a two-hundred day moving average of $52.83. The company has a market cap of $149.53 billion, a P/E ratio of 23.66, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.